May 2022 in “Gastroenterology” Targeting NETs may help reduce fibrosis in Crohn's disease.
4 citations
,
January 2011 Phenylpropanoid sucrose esters show potential as anticancer agents.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
29 citations
,
October 2016 in “Cell death and differentiation” ΔNp63α stops TAp73β from working in skin cancer by blocking its access to specific genes, not by directly interacting with it.
2 citations
,
November 2018 in “Indian Journal of Pharmaceutical Education” The developed model can predict effective 5-alpha-reductase enzyme inhibitors.
January 2026 in “American Journal of Translational Research” The metoprolol-spironolactone combination improves heart function in patients with coronary heart disease and heart failure.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia” 3 citations
,
January 2019 in “Indian Journal of Drugs in Dermatology” Certain cancer drugs can cause skin issues like rashes and itching.
58 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Pioglitazone may help treat lichen planopilaris, but more research is needed.
11 citations
,
June 2019 in “Journal of dermatology” New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
68 citations
,
January 2014 in “Dermatology research and practice” Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
84 citations
,
December 2018 in “Genetics in Medicine” Pegvaliase is recommended for treating adults with phenylketonuria.
Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
January 2022 in “Drugs of Today”
January 2025 in “International Journal of Advancement in Life Sciences Research” Drug repurposing can be cost-effective but needs more testing for safety and effectiveness.
29 citations
,
February 2021 in “Cancers” Ion channels play a key role in ovarian cancer growth and treatment resistance.
26 citations
,
February 1998 in “Chemico-Biological Interactions” Scientists identified three genes important for processing certain brain chemicals, thyroid hormones, and medications.
July 2024 in “Experimental Dermatology” AP collagen peptides help hair grow and improve hair health.
3 citations
,
July 2023 in “International Journal of Trichology” DPCP can help regrow hair in some people with severe alopecia.
2 citations
,
January 2025 in “Journal of Nanobiotechnology” A new engineered treatment shows promise in curing heart fibrosis.
January 2012 in “Zhongguo quanke yixue” The treatment was effective and tolerable for advanced gastric cancer.
19 citations
,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
June 2025 in “Proceedings of the National Academy of Sciences” A PIK3CA mutation in Schwann cells causes severe nerve damage and increased glycolysis, but early treatment can help.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
8 citations
,
March 2023 in “PubMed” JAK inhibitors show promise in treating difficult skin diseases.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
Skin tumor cells in patients with tuberous sclerosis have higher levels of a protein called cathepsin B.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.